Update: The FDA has told compounding pharmacies they may resume production of tirzepatide products while the agency further investigates supply.
Ashley Gallagher
Advertisement
Articles by Ashley Gallagher
Proposed indications for the investigational factor XIa inhibitor are: stroke prevention after acute ischemic stroke or high-risk transient ischemic attack; recent acute coronary syndrome; and atrial fibrillation.
Advertisement
Latest Updated Articles
Milvexian, FXIa Inhibitor, Wins US FDA Fast Track Designation for 3 Indications in Phase 3 Trial ProgramPublished: June 7th 2023 | Updated:
Advertisement
Advertisement
Trending on Patient Care Online
1
Menopause Education Wholly Inadequate for Physician Associates, According to New Survey Results
2
Menopause Education Lags in Residency Training Across Primary Care Specialties
3
Timing of Menopausal Hormone Therapy May Impact Biomarkers of Alzheimer Disease
4
Menopause: A Constellation of Syndromes Across 13 Body Systems
5
